Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.
about
Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cellsGerm-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humansPhosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas.Interleukin-6 in bone metastasis and cancer progression.A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype.GP130 activation induces myeloma and collaborates with MYC.Sarcophine-diol, a skin cancer chemopreventive agent, inhibits proliferation and stimulates apoptosis in mouse melanoma B₁₆F₁₀ cell line.STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferationSTAT proteins as novel targets for cancer drug discovery.The elements of human cyclin D1 promoter and regulation involved.Acromegaly due to a Macroinvasive Plurihormonal Pituitary Adenoma and a Rectal Carcinoid Tumor.The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis.Cancer cell signaling pathways targeted by spice-derived nutraceuticals.Differential cell fates induced by all-trans retinoic acid-treated HL-60 human leukemia cellsEstrogenic or antiestrogenic therapies for multiple myeloma?The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Examining the role of cyclin D1 in breast cancer.Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.Novel STAT binding elements mediate IL-6 regulation of MMP-1 and MMP-3.Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.IGF-1 stimulated upregulation of cyclin D1 is mediated via STAT5 signaling pathway in neuronal cells.Functional Imaging of Pheochromocytoma with Ga-DOTATOC and C-HED in a Genetically Defined Rat Model of Multiple Endocrine NeoplasiaINCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell supportJanus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver.Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer.Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.Characterization of MENX-associated pituitary tumours.Expression of Epstein-Barr virus (EBV)-encoded latent membrane proteins and STAT3 activation in nasopharyngeal carcinoma.[Molecular pathology of plasma cell neoplasms].Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.Anti-myeloma Effects of Icariin Are Mediated Through the Attenuation of JAK/STAT3-Dependent Signaling Cascade.Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma.
P2860
Q21261315-DA40A202-74A1-4EEF-9444-B54725FB7498Q24679314-9C00A5CB-EA66-4FC4-B331-E893BEA75D51Q30311912-936217FB-008F-4B34-B039-907C88E7205EQ33588550-5EC1CD28-1DB2-45C4-A78E-BD74AB3B6272Q34051820-4A8AC14F-AAB6-4AD0-BF69-5591452C923AQ34649802-7C788F83-8442-49CA-B204-B7E9D472FA22Q35145350-117DEDD8-2FFC-4216-A0CD-37BE790EC72FQ35759916-316D7D09-59A4-4AB8-907C-EE2961890E5AQ35770784-4A99A33C-1CFB-4782-A5BC-F279C90AFB67Q35911116-CEF063CB-9060-43DE-84BA-3089C97D565FQ36002446-7C7CE360-6F17-484C-AE56-6D9821CB5751Q36127632-719737F3-C68F-4AC1-A134-29A69E14E3D5Q36216258-F646BDF7-F73B-4D41-914F-C2F2D012E168Q36289029-61C24CC1-035C-43E3-8E13-9164897D794FQ36819371-646B5904-4C8E-4965-B71E-AAA72732AF87Q36838578-776B96BE-0459-43D8-8174-87E7B5A7B127Q36948728-3C194E78-4F5E-450C-8A7D-F1AA148D74E5Q37300043-9EBB10AF-39FE-47BB-88AD-C659E1026093Q37697253-51828E6E-D7BA-4661-9B70-2A2666975D35Q37889965-A5D7F06D-2064-4F6A-BF5D-D2E1D3AE5018Q38161731-B6C1FA8A-EE2E-46D2-BC12-9FF8B482E732Q38164139-B9CCD679-9989-46BE-9320-2705A451A79BQ38619063-3FEC48F9-ACD6-41C0-8F99-935FEF47A1BDQ38744300-60CC4A3A-E8FB-4971-8BC4-E1C7D86C736FQ39179345-2B6B228E-71AF-4760-A044-2C8D8BA7F594Q39729032-FB3218A1-642B-4F6E-AF89-786ADA2E68FAQ39752237-B79F40C6-8B85-49FC-B350-1D846F646FEEQ39896286-8279F874-B077-4A2E-BDCB-43A47B00F774Q40130124-AC59A8A2-763D-4A2A-9D7C-7117A5F89B64Q40216755-DC329E68-F062-47DE-B3B9-0A185365174FQ41818628-FED357B7-90A1-4D08-9722-A7AEB4730177Q42742643-1F60BC8C-2EF0-4E98-AA53-88107C7AABF3Q43005372-011061DE-5822-41E2-98BF-EEC481B96548Q43803032-2D8CAF66-6C5A-49D1-A4D6-B4E5AEB4EDBDQ45411309-DF33365C-896A-4970-94A5-AE92D90701A5Q51152310-B66D463C-285A-46A9-AE5D-DCC663926D86Q53087536-C10A3E35-3BED-4EDD-A6F5-C39F0A14EF79Q55049042-C5DE74D5-715E-4D70-909D-CA5C287776FBQ55281764-AC2A9476-50E6-4080-B9C4-B91DE5EA7349
P2860
Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Analysis of signal transducer ...... are mutually exclusive events.
@ast
Analysis of signal transducer ...... are mutually exclusive events.
@en
type
label
Analysis of signal transducer ...... are mutually exclusive events.
@ast
Analysis of signal transducer ...... are mutually exclusive events.
@en
prefLabel
Analysis of signal transducer ...... are mutually exclusive events.
@ast
Analysis of signal transducer ...... are mutually exclusive events.
@en
P2093
P2860
P50
P1476
Analysis of signal transducer ...... are mutually exclusive events.
@en
P2093
Heinz Höfler
Katja Specht
Marcus Kremer
Michaela Nathrath
Robert Schaich
P2860
P304
P356
10.1016/S0002-9440(10)64278-2
P407
P577
2003-05-01T00:00:00Z